文献速递心力衰竭与心肌病

恩格列净对射血分数保留心力衰竭患者心衰恶化事件的影响:EMPEROR-Preserved 试验

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial.
PubMed 文献 · Circulation · 2021-08-29

EMPEROR-Preserved 试验将 5988 例射血分数>40% 的心衰患者随机分配至恩格列净 10 mg 每日一次或安慰剂,中位随访 26 个月。恩格列净降低了心血管死亡、心衰住院或需静脉治疗的紧急心衰就诊的复合风险(HR 0.77,95%CI 0.67-0.87,P<0.0001),并减少了需重症监护的心衰住院总数、需血管升压药或正性肌力药的总住院数以及门诊利尿剂强化,NYHA 功能分级改善更常见。

要点

  • 恩格列净降低心血管死亡、心衰住院或紧急心衰就诊复合风险(HR 0.77)。
  • 恩格列净减少需重症监护的心衰住院和需升压/正性肌力药的总住院。
  • 恩格列净减少门诊利尿剂强化并改善 NYHA 分级,获益在 18 天即显著。

核心结论

  • 在射血分数保留的心衰患者中,恩格列净对住院和门诊心衰恶化事件的风险与严重程度产生有意义的、早期且持续的降低。

研究设计与样本

  • 多中心随机双盲安慰剂对照试验,纳入 5988 例 NYHA II-IV 级、射血分数>40% 的心衰患者,随机接受恩格列净 10 mg 每日一次或安慰剂,中位随访 26 个月。

主要发现

  • 恩格列净组 432 例 vs 安慰剂组 546 例发生心血管死亡、心衰住院或需静脉治疗的紧急心衰就诊复合终点(HR 0.77,95%CI 0.67-0.87,P<0.0001),随机后 18 天即达统计学显著。
  • 恩格列净减少需重症监护的心衰住院总数(HR 0.71,95%CI 0.52-0.96,P=0.028)和需血管升压药或正性肌力药的总住院数(HR 0.73,95%CI 0.55-0.97,P=0.033)。
  • 恩格列净组门诊利尿剂强化患者更少(482 vs 610;HR 0.76,95%CI 0.67-0.86,P<0.0001),NYHA 功能分级改善的可能性高 20%-50%,12 周时显著并维持至少 2 年。
  • 总心衰住院获益在射血分数>40%至<50%和 50%至<60%患者中相似,但在更高射血分数时减弱。

临床怎么用

  • 对于射血分数>40% 的心衰患者,可考虑使用恩格列净 10 mg 每日一次以降低心衰恶化事件风险。
  • 恩格列净的获益在随机后 18 天即显现,早期即可观察到对门诊利尿剂强化和 NYHA 分级的改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction, but additional data are needed about its effect on inpatient and outpatient heart failure events. METHODS: We randomly assigned 5988 patients with class II through IV heart failure with an ejection fraction of >40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to usual therapy, for a median of 26 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points. RESULTS: Empagliflozin reduced the combined risk of cardiovascular death, hospitalization for heart failure, or an emergency or urgent heart failure visit requiring intravenous treatment (432 versus 546 patients [empagliflozin versus placebo, respectively]; hazard ratio, 0.77 [95% CI, 0.67-0.87]; P<0.0001). This benefit reached statistical significance at 18 days after randomization. Empagliflozin reduced the total number of heart failure hospitalizations that required intensive care (hazard ratio, 0.71 [95% CI, 0.52-0.96]; P=0.028) and the total number of all hospitalizations that required a vasopressor or positive inotropic drug (hazard ratio, 0.73 [95% CI, 0.55-0.97]; P=0.033). Compared with patients in the placebo group, fewer patients in the empagliflozin group reported outpatient intensification of diuretics (482 versus 610; hazard ratio, 0.76 [95% CI, 0.67-0.86]; P<0.0001), and patients assigned to empagliflozin were 20% to 50% more likely to have a better New York Heart Association functional class, with significant effects at 12 weeks that were maintained for at least 2 years. The benefit on total heart failure hospitalizations was similar in patients with an ejection fraction of >40% to <50% and 50% to <60%, but was attenuated at higher ejection fractions. CONCLUSIONS: In patients with heart failure with preserved ejection fraction, empagliflozin produced a meaningful, early, and sustained reduction in the risk and severity of a broad range of inpatient and outpatient worsening heart failure events. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer M, Butler J, Zannad F, et al. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation. 2021. PMID: 34459213. doi:10.1161/CIRCULATIONAHA.121.056824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。